Ism1 deficiency in mice exacerbates bleomycin-induced pulmonary fibrosis with enhanced cellular senescence and delayed fibrosis resolution.

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by the thickening and scarring of lung tissue. The exact cause of IPF is unknown, and treatment options are limited. In this study, researchers used a mouse model to investigate the pathophysiological mechanisms of IPF and explore potential therapies. They found that a protein called ISM1 plays a protective role against pulmonary fibrosis. ISM1 deficiency exacerbated lung fibrosis and delayed the resolution of fibrosis. This study highlights the importance of ISM1 in both the progression and resolution phases of pulmonary fibrosis and suggests further research on manipulating ISM1 levels for potential interventions or treatments. [Extracted from the article]

Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)